Treatment of Erythrodermic, Severe or Unstable Plaque, and Unstable Pustular Psoriasis
Erythrodermic psoriasis, severe or unstable plaque psoriasis, and unstable pustular psoriasis are acute, high-severity presentations that require a different management approach from stable chronic disease. These scenarios share a need for rapid disease control and prompt clinical decision-making.
Clinical Scenarios
Erythrodermic psoriasis
Severe or unstable plaque psoriasis
Unstable pustular psoriasis
Treatment Approach
Short-term systemic crisis management is indicated for these acute presentations — cyclosporine is among the agents used to achieve rapid stabilisation until a long-term treatment strategy can be established. Full regimen details, dosing, and transition guidance are in the complete protocol.
Clinical Goals
- Rapid control of active disease
- Observable improvement within 1 to 2 weeks of initiation
- Skin clearance achievable within approximately 4 weeks
References
DOI: 10.1016/j.jaad.2019.08.049
- Cyclosporine is recommended for short-term crisis management of severe or unstable plaque, erythrodermic, or pustular psoriasis until the patient can be transitioned to a medication appropriate for long-term use.
- It is an excellent choice for the rapid control of severe, unstable plaque, pustular, or erythrodermic psoriasis in children.
- Improvement may be observed within 1 to 2 weeks, although the full effect is most often seen between 4 and 8 weeks after initiation.
View source ↗